Expandable cell populations from brain biopsies of living subjects

Abstract

The present invention relates to a method of producing expandable cultured brain cells. The brain cells are neurotrophic factor (NTF) positive. The expandable cultured brain cells are obtained by culturing a biopsy obtained from the cortical and/or subcortical brain region of a living subject. The biopsies can be obtained during neurosurgical procedures such as deep brain stimulation. The expandable cultured brain cells of the present invention are useful for the treatment of neurological diseases and other medical conditions.

1 .- 62 . (canceled) 
     
     
         63 . A method of producing a population of expanded glial progenitor brain cells characterized as expressing nestin, an oligodendrogial protein and a mesenchymal protein and that express at least one neurotrophic factor (NTF) selected from a glial cell line-derived neurotrophic factor (GDNF), a brain-derived neurotrophic factor (BDNF), or a cerebral dopamine neurotrophic factor (CDNF), the method comprising:
 (a) culturing brain cells of a cortical and/or subcortical brain regions of a living subject under conditions suitable for cell expansion,   (b) passaging the cells of part (a) for a minimum of 4 passages and testing the passaged cells for expression of nestin, the oligodendroglial protein, the mesenchymal protein and the at least one NTF,   (c) isolating the cells that express the nestin, oligodendroglial protein, the mesenchymal protein and the at least one NTF thereby producing the population of expanded progenitor brain cells that express nestin, oligodendroglial protein, the mesenchymal protein and the at least one NTF.   
     
     
         64 . The method of  claim 63 , wherein the living subject has a neurological disorder. 
     
     
         65 . The method of  claim 64 , wherein the neurological disorder is selected from Parkinson's disease, Alzheimer's disease, Huntington disease and brain tissue damage caused by a cerebral ischemia. 
     
     
         66 . The method of  claim 64 , wherein the method further comprises a heterologous implant of the cells isolated in step (c) in a patient having the neurological disorder. 
     
     
         67 . The method of  claim 66 , wherein the neurological disorder is selected from Parkinson's disease, Alzheimer's disease, Huntington disease and brain tissue damage caused by a cerebral ischemia. 
     
     
         68 . The method of  claim 67 , wherein the neurological disorder is Parkinson's disease. 
     
     
         69 . The method of  claim 64 , wherein the method further comprises an autologous implant of the cells isolated in step (c) in a patient having the neurological disorder. 
     
     
         70 . The method of  claim 69 , wherein the neurological disorder is selected from Parkinson's disease, Alzheimer's disease, Huntington disease and brain tissue damage caused by a cerebral ischemia. 
     
     
         71 . The method of  claim 69 , wherein the neurological disorder is Parkinson's disease. 
     
     
         72 . The method of  claim 63 , wherein the method further comprises genetically or physiologically manipulating the population of expanded brain cell to underexpress, express or overexpress a molecule of interest. 
     
     
         73 . The method of  claim 63 , wherein step (a) comprises culturing the brain cells in a lysine coated substrate. 
     
     
         74 . The method of  claim 63 , wherein the method further comprises optimizing a culture medium by placing the population of expanded progenitor brain cells that express nestin, oligodendroglial protein, the mesenchymal protein and the at least one NTF in the culture medium. 
     
     
         75 . The method of  claim 74 , wherein the method further comprises cultivating cells derived from the central nervous system in the optimized culture medium.